目的 探討細(xì)菌溶解產(chǎn)物聯(lián)合阿奇霉素注射劑治療反復(fù)性兒童呼吸道感染的臨床療效。方法 選擇2019年1月—2021年10月在淮南陽(yáng)光新康醫(yī)院兒科診療的90例呼吸道感染患兒，隨機(jī)分為對(duì)照組和治療組，每組各45例。對(duì)照組患兒靜脈滴注鹽酸阿奇霉素注射液，0.15 g/次加入到5%葡萄糖注射液250 mL，1次/d。在對(duì)照組的基礎(chǔ)上，治療組空腹口服細(xì)菌溶解產(chǎn)物膠囊，1粒/次，1次/d。兩組患兒治療5 d。觀察兩組患兒臨床療效，比較治療前后兩組患兒癥狀好轉(zhuǎn)時(shí)間，血清因子白細(xì)胞介素-6（IL-6）、降鈣素原（PCT）、腫瘤壞死因子-α（TNF-α）和C反應(yīng)蛋白（CRP）水平及不良反應(yīng)情況。結(jié)果 治療后，治療組總有效率為97.78%，明顯高于對(duì)照組的77.78%（P＜0.05）。治療后，治療組發(fā)熱、咳嗽、鼻塞、流涕好轉(zhuǎn)時(shí)間均明顯早于對(duì)照組（P＜0.05）。治療后，兩組患兒血清因子IL-6、PCT、TNF-α、CRP水平均明顯降低（P＜0.05），且治療組明顯低于對(duì)照組（P＜0.05）。治療期間，治療組患者不良反應(yīng)發(fā)生率為6.67%，明顯低于對(duì)照組的13.33%（P＜0.05）。結(jié)論 細(xì)菌溶解產(chǎn)物聯(lián)合阿奇霉素注射劑治療反復(fù)性兒童呼吸道感染能有效改善癥狀，有效降低機(jī)體炎性反應(yīng)。

Objective To investigate the clinical effect of bacterial lysate combined with azithromycin in treatment of recurrent childhood respiratory tract infections. Methods Children (90 cases) with recurrent respiratory tract infections in Huainan Yangguang Xinkang Hospital from January 2019 to October 2021 were randomly divided into control and treatment group, and each group had 45 cases. Children in the control group were iv administered with Azithromycin Hydrochloride Injection, 0.15 g added into 5% glucose injection 250 mL, once daily. Children in the treatment group were po administered with Bacterial Lysates (Broncho-Vaxom) on the basis of the control group, 1 grain/time, once daily. Children in two groups were treated for 5 d. After treatment, the clinical evaluation was evaluated, the improvement time of symptoms, the levels of IL-6, PCT, TNF-α, and CRP, and adverse reactions in two groups before and after treatment were compared. Results After treatment, the clinical effective rate in the treatment group was 97.78%, which was significantly higher than 77.78% in the control group (P < 0.05). After treatment, the improvement time of fever, cough, nasal congestion, and runny nose in the treatment group was significantly earlier than that in the control group (P < 0.05). After treatment, the serum levels of IL-6, PCT, TNF-α, and CRP were significantly decreased in two groups (P < 0.05), and the level in the treatment group was significantly lower than that in the control group (P < 0.05). During the treatment, the incidence of adverse reactions in the treatment group was 6.67%, which was significantly lower than 13.33% in the control group (P < 0.05). Conclusion Bacterial lysate combined with azithromycin in treatment of recurrent childhood respiratory tract infections can effectively improve the symptoms, and reduce the inflammatory reaction.

R914